IMMUNOGEN

Substance
Name: human PNAd
Origin: immunoisolated from human tonsil lysates by monoclonal Ab affinity chromatography. associated with HEV’S

Chemical Composition: glycoprotein
Developmental Stage: n/a

IMMUNIZATION PROTOCOL

Donor Animal: rat
Species: see reference below
Strain: " "
Sex: " "
Organ and tissue: spleen

Immunization
Dates immunized: see reference below
Amount of antigen: " "
Route of immunization: " "
Adjuvant: " "

FUSION

Date: 4-6-92
Myeloma cell line
Species: mouse
Designation: SP2/0

MONOCLONAL ANTIBODY

Isotype: rat IgG2c
Specificity:
Cell binding: does not block L-selectin binding of human lymphocytes.
Immunohistology: positive on human tonsil HEV and P.L.N. HEV. negative on human appendix HEV and chronically inflamed skin.
Antibody competition: can cross-block with other JG Abs on tonsil sections; can cross-block with other JG Abs and MECA-79 on purified PNAd in ELISAS.
Species Specificity: does not recognize mouse PNAd, only human PNAd.

ANTIGEN

Chemical properties: neuraminidase sensitive, sialic acid-dependent
Molecular weight: mostly about 150 kDa
Characterization:
Immunoprecipitation: immunoisolated by monoclonal Ab affinity chromatography; SDS page gel, Western blot
Immunoblotting: polyacrylamide gel electrophoresis to nitrocellulose membrane via Trans blot; alkaline phosphatase IgG, then Western blot substrate.
Purification: tissue extracts passed over agarose, then monoclonal Ab affinity column. purity assessed by iodination followed by SDS page and autoradiography.
Amino acid sequence analysis: not known
Functional effects: rolling assays-done only with materials isolated from lymphoid tissues, not from in-vitro cultured cells.
Immunohistochemistry: frozen sections of human tonsils, p.l.n., appendix, or inflamed skin incubated with JG supernatant, PE anti-rat IgG, and FITC conjugated MECA-79. (Continued)

ACKNOWLEDGMENTS STATEMENT

We have been asked by NICHD to ensure that all investigators include an acknowledgment in publications that benefit from the use of the DSHB's products. We suggest that the following statement be used:

“The (select: hybridoma, monoclonal antibody, or protein capture reagent,) developed by [Investigator(s) or Institution] was obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.”

Please send copies of all publications resulting from the use of Bank products to:

Developmental Studies Hybridoma Bank
Department of Biology
The University of Iowa
028 Biology Building East
Iowa City, IA 52242